Imp3 expression in urothelial carcinomas of the urinary bladder | Zendy

Nihal Ozkalay Ozdemir | Zendy; Nilay Şen Türk | Zendy; Ender Düzcan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Imp3 expression in urothelial carcinomas of the urinary bladder

Author(s) -

Nihal Ozkalay Ozdemir,

Nilay Şen Türk,

Ender Düzcan

Publication year - 2011

Publication title -

turkish journal of pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.305

H-Index - 14

eISSN - 1309-5730

pISSN - 1018-5615

DOI - 10.5146/tjpath.2010.01044

Subject(s) - urothelium , immunohistochemistry , urothelial carcinoma , medicine , urothelial cell , stage (stratigraphy) , urinary bladder , pathology , carcinoma , bladder cancer , urology , cancer , biology , paleontology

Superficial tumors including Ta, Tis, and T1 make up 75% of urothelial carcinomas of the bladder. While the behavior of these superficial urothelial cancers is relatively benign, invasive tumors have a significant mortality rate. However, Ta and T1 tumors might display different biological behavior. There is therefore a great need for biomarkers that can accurately distinguish the behavior of urothelial carcinomas in addition to tumor grade and stage. Our aim was to determine the immunohistochemical expression profile of insulin like growth factor II mRNA binding Protein 3 (IMP3) and its correlation with tumor stage and grade in benign urothelium and bladder urothelial carcinomas.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research